NASDAQ:VIE

Viela Bio Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$53.01
0.00 (0.00 %)
(As of 03/15/2021)
Add
Compare
Today's Range
$53.01
Now: $53.01
$53.01
50-Day Range
$52.92
MA: $53.01
$53.20
52-Week Range
$25.02
Now: $53.01
$65.00
VolumeN/A
Average Volume1.07 million shs
Market Capitalization$2.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.43

Competitors

Viela Bio (NASDAQ:VIE) Vs. RDY, TEVA, BHC, JAZZ, UTHR, and MRVI

Should you be buying VIE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Viela Bio, including Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), and Maravai LifeSciences (MRVI).

Dr. Reddy's Laboratories (NYSE:RDY) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 47.0% of Viela Bio shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 31.5% of Viela Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Dr. Reddy's Laboratories and Viela Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00303.00
Viela Bio05202.29

Dr. Reddy's Laboratories presently has a consensus target price of $70.00, indicating a potential upside of 1.89%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Viela Bio's higher probable upside, analysts plainly believe Viela Bio is more favorable than Dr. Reddy's Laboratories.

Profitability

This table compares Dr. Reddy's Laboratories and Viela Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Viela BioN/A-33.97%-31.49%

Volatility and Risk

Dr. Reddy's Laboratories has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Valuation and Earnings

This table compares Dr. Reddy's Laboratories and Viela Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion4.93$259 million$2.7924.62
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55

Dr. Reddy's Laboratories has higher revenue and earnings than Viela Bio. Viela Bio is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats Viela Bio on 9 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

51.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 47.0% of Viela Bio shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 31.5% of Viela Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Teva Pharmaceutical Industries and Viela Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries18402.23
Viela Bio05202.29

Teva Pharmaceutical Industries presently has a consensus target price of $12.2222, indicating a potential upside of 19.83%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Teva Pharmaceutical Industries' higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Viela Bio.

Profitability

This table compares Teva Pharmaceutical Industries and Viela Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
Viela BioN/A-33.97%-31.49%

Volatility and Risk

Teva Pharmaceutical Industries has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Valuation and Earnings

This table compares Teva Pharmaceutical Industries and Viela Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.66$-998,000,000.00$2.314.42
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55

Viela Bio has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Viela Bio is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Summary

Teva Pharmaceutical Industries beats Viela Bio on 9 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Valuation and Earnings

This table compares Bausch Health Companies and Viela Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.22$-1,788,000,000.00$4.436.65
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55

Viela Bio has lower revenue, but higher earnings than Bausch Health Companies. Viela Bio is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Bausch Health Companies and Viela Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies14702.50
Viela Bio05202.29

Bausch Health Companies presently has a consensus target price of $32.5833, indicating a potential upside of 10.56%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, equities analysts plainly believe Bausch Health Companies is more favorable than Viela Bio.

Profitability

This table compares Bausch Health Companies and Viela Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Viela BioN/A-33.97%-31.49%

Institutional & Insider Ownership

62.9% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 47.0% of Viela Bio shares are owned by institutional investors. 12.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 31.5% of Viela Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Bausch Health Companies has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Summary

Bausch Health Companies beats Viela Bio on 10 of the 14 factors compared between the two stocks.

Viela Bio (NASDAQ:VIE) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Viela Bio and Jazz Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55
Jazz Pharmaceuticals$2.16 billion4.36$523.37 million$14.6011.47

Jazz Pharmaceuticals has higher revenue and earnings than Viela Bio. Viela Bio is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viela Bio and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viela BioN/A-33.97%-31.49%
Jazz Pharmaceuticals7.86%20.16%10.85%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Viela Bio and Jazz Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viela Bio05202.29
Jazz Pharmaceuticals111702.84

Viela Bio currently has a consensus price target of $57.00, indicating a potential upside of 7.53%. Jazz Pharmaceuticals has a consensus price target of $187.3684, indicating a potential upside of 11.95%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Viela Bio.

Institutional and Insider Ownership

47.0% of Viela Bio shares are owned by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. 31.5% of Viela Bio shares are owned by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Viela Bio has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats Viela Bio on 12 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Viela Bio (NASDAQ:VIE) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares United Therapeutics and Viela Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.45 billion6.44$-104,500,000.00($2.39)-87.59
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55

Viela Bio has lower revenue, but higher earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares United Therapeutics and Viela Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics33.25%15.48%11.31%
Viela BioN/A-33.97%-31.49%

Analyst Ratings

This is a breakdown of current ratings and price targets for United Therapeutics and Viela Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00703.00
Viela Bio05202.29

United Therapeutics presently has a consensus target price of $219.5714, suggesting a potential upside of 4.90%. Viela Bio has a consensus target price of $57.00, suggesting a potential upside of 7.53%. Given Viela Bio's higher possible upside, analysts plainly believe Viela Bio is more favorable than United Therapeutics.

Institutional and Insider Ownership

90.1% of United Therapeutics shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 10.9% of United Therapeutics shares are held by insiders. Comparatively, 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

United Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Summary

United Therapeutics beats Viela Bio on 10 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Viela Bio (NASDAQ:VIE) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Maravai LifeSciences and Viela Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55

Maravai LifeSciences has higher earnings, but lower revenue than Viela Bio.

Profitability

This table compares Maravai LifeSciences and Viela Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Viela BioN/A-33.97%-31.49%

Analyst Ratings

This is a breakdown of current ratings and price targets for Maravai LifeSciences and Viela Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Viela Bio05202.29

Maravai LifeSciences presently has a consensus target price of $38.1250, suggesting a potential upside of 6.20%. Viela Bio has a consensus target price of $57.00, suggesting a potential upside of 7.53%. Given Viela Bio's higher possible upside, analysts plainly believe Viela Bio is more favorable than Maravai LifeSciences.

Institutional and Insider Ownership

47.0% of Viela Bio shares are held by institutional investors. 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Viela Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$68.70flat$11.28 billion$2.32 billion56.78
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.20flat$11.19 billion$16.89 billion-2.77Upcoming Earnings
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.47flat$10.51 billion$8.60 billion-5.41
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$167.52flat$9.44 billion$2.16 billion52.85Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$209.33flat$9.32 billion$1.45 billion19.80News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.83flat$9.14 billionN/A0.00Analyst Upgrade
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.90flat$8.27 billion$40.56 million-16.39
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$160.84flat$8.26 billion$3.34 million-20.89
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$70.99flat$7.37 billion$87.99 million-84.51
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$108.87flat$7.31 billion$103.71 million-24.80Analyst Report
Insider Selling
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.47flat$6.85 billion$311.33 million-127.02Analyst Downgrade
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$131.85flat$6.72 billion$14.98 million-16.06Analyst Downgrade
Unusual Options Activity
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.46flat$5.98 billion$1.12 billion88.46Analyst Report
Analyst Revision
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$41.09flat$5.78 billion$150,000.00-19.38Analyst Report
Analyst Revision
News Coverage
Perrigo logo
PRGO
Perrigo
2.3$42.63flat$5.69 billion$4.84 billion-710.38Upcoming Earnings
Dividend Announcement
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.38flat$5.67 billion$380.83 million-9.13Analyst Report
News Coverage
Allakos logo
ALLK
Allakos
1.7$107.16flat$5.64 billionN/A-39.11
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.40flat$5.50 billion$66.51 million17.42Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$82.44flat$5.40 billion$1.00 billion-12.49Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.5$73.26flat$5.13 billion$85.54 million0.00Insider Selling
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$75.21flat$4.66 billionN/A-6.13Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.72flat$4.36 billion$6.87 million-7.22Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.75flat$4.33 billion$204.89 million-37.19
I-Mab logo
IMAB
I-Mab
1.2$58.42flat$4.20 billion$4.31 million-2.02News Coverage
Gap Down
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.81flat$4.09 billion$806.43 million-9.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.19flat$3.85 billion$117.91 million-11.19Upcoming Earnings
Insider Selling
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.07flat$3.70 billionN/A-6.21Upcoming Earnings
Analyst Report
News Coverage
LEGN
Legend Biotech
1.2$28.28flat$3.63 billion$64.39 million0.00Analyst Report
Insmed logo
INSM
Insmed
1.2$35.02flat$3.62 billion$136.47 million-13.47Upcoming Earnings
News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.31flat$3.61 billionN/A-20.89
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$20.10flat$3.60 billion$114.62 million-8.10
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$63.12flat$3.54 billion$1.11 billion20.30Upcoming Earnings
High Trading Volume
News Coverage
Gap Up
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$39.76flat$3.37 billionN/A0.00News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.87flat$3.34 billion$339.08 million-12.13Analyst Revision
Alkermes logo
ALKS
Alkermes
1.2$20.92flat$3.33 billion$1.17 billion-45.48Upcoming Earnings
Insider Selling
Analyst Revision
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.51flat$3.31 billion$26.52 million-8.06Unusual Options Activity
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$46.82flat$3.29 billion$306.98 million-6.70
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.26flat$3.23 billion$36.13 million-69.04News Coverage
Arvinas logo
ARVN
Arvinas
1.7$66.26flat$3.21 billion$42.98 million-25.88Upcoming Earnings
Analyst Report
News Coverage
MorphoSys logo
MOR
MorphoSys
0.3$23.18flat$3.00 billion$80.43 million110.39
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.39flat$2.93 billion$644.77 million-10.75
OPKO Health logo
OPK
OPKO Health
1.9$4.37flat$2.93 billion$901.90 million-24.28News Coverage
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$107.45flat$2.93 billionN/A-53.46
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$64.45flat$2.86 billion$421.03 million22.69News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.53flat$2.74 billion$25 million-9.51Insider Selling
Analyst Revision
News Coverage
Organogenesis logo
ORGO
Organogenesis
1.0$21.33flat$2.72 billion$260.98 million-355.50News Coverage
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.88flat$2.72 billion$306.49 million26.83
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$43.16flat$2.68 billion$2.11 million-9.34Analyst Report
Unusual Options Activity
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$44.50flat$2.67 billionN/A-24.45
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.87flat$2.61 billion$182.24 million-8.58Analyst Upgrade
Insider Selling
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.